Report 78: Thirty-Two Percent Of Pfizer's Post-Marketing Respiratory Adverse Event Patients Died, Yet Pfizer Found No New Safety Signals.

 Of the 137 relevant adverse events, 126, or 92%, were categorized as "Serious," which, according to the Food and Drug Administration, includes patient outcomes such as death, life-threatening events, hospitalizations, and disability or permanent damage.

Diagnoses included: "Severe acute respiratory syndrome".

"Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this website was developed for the 2003 SARS epidemic. But some guidelines are still being used. Any new SARS updates will be posted on this website." The World Health Organization agrees with that assessment.

"Respiratory failure," 32% of the adverse events, includes all cases requiring a mechanical ventilator.

Acute respiratory distress syndrome, a lung injury where fluid leaks from the blood vessels into the lung tissue as well as the air spaces resulting in stiffness of the lung.

For the adverse events that had a record of time from injection to onset, the range was from within 24 hours to 18 days with half of the events reported at one day.

Despite 32% of patients in this SOC dying, Pfizer concluded, "This cumulative case review does not raise new safety issues. Surveillance will continue."

https://dailyclout.io/report-78-thirty-two-percent-of-patients-died/